MVV:ARCA-ProShares Ultra MidCap400

ETF | Drug Manufacturers | NYSE Arca

Last Closing

USD 39.29

Change

-0.15 (-0.38)%

Market Cap

USD 0.12B

Volume

0.24M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the S&P MidCap 400?. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index is a measure of mid-size company U.S. stock market performance. It is a float-adjusted, market capitalization-weighted index of 400 U.S. operating companies and real estate investment trusts selected through a process. The fund is non-diversified.

Inception Date: 19/06/2006

Primary Benchmark: S&P MidCap 400 TR

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 1.06%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Symbol Company Name Allocation
TARS Tarsus Pharmaceuticals Inc 0.52 %
Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-10-16 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Mer Price(Change) Market Cap
SCYB Schwab Strategic Trust 0.00 %

+0.15 (+0.29%)

N/A

ETFs Containing MVV

IEDY:SW iShares V PLC - iShares E.. 1.82 % 0.00 %

+0.01 (+0.09%)

USD 0.60B
DVYE iShares Emerging Markets .. 0.00 % 0.49 %

+0.21 (+0.09%)

USD 0.68B
IEDY:LSE iShares EM Dividend UCITS.. 0.00 % 0.00 %

N/A

USD 0.60B
SEDY:LSE iShares V Public Limited .. 0.00 % 0.00 %

-0.75 (0.09%)

USD 0.60B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 29.24% 74% C 84% B
Dividend Return 0.59% 29% F 9% A-
Total Return 29.83% 74% C 83% B
Trailing 12 Months  
Capital Gain -4.08% 42% F 36% F
Dividend Return 0.66% 18% F 8% B-
Total Return -3.42% 39% F 33% F
Trailing 5 Years  
Capital Gain 93.58% 76% C+ 88% B+
Dividend Return 3.10% 43% F 10% F
Total Return 96.68% 76% C+ 86% B+
Average Annual (5 Year Horizon)  
Capital Gain 13.55% 79% B- 86% B+
Dividend Return 13.92% 79% B- 83% B
Total Return 0.37% 41% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 23.82% 29% F 28% F
Risk Adjusted Return 58.42% 68% D+ 67% D+
Market Capitalization 0.12B 79% B- 27% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.